VANCOUVER, British Columbia, February 19, 2019 — Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) wishes to announces that it has entered into a debt settlement agreement with its Interim CEO and CFO, Mr. Peter McFadden, to settle management fees in the amount of $31,500 by the issuance of 273,913 common shares at a deemed price of $0.115 per share. Veritas also announces that it has cancelled stock options previously granted to directors and officers entitling them to purchase an aggregate of 1,200,000 common shares at a price of $0.52 per share on or before May 2, 2024.

About Veritas Pharma

Veritas has developed intellectual property and clinical data relating to various cannabis strains and products. It is the Company’s aim to advance the science behind medicinal cannabis, by developing cannabis-based treatments for specific disease conditions. The Company is also focused on investigating opportunities to acquire income-producing assets in the cannabis industry. Moreover, Veritas intends to leverage its management expertise to enter into mergers and acquisitions with suitable cannabis-industry participants, with a view to generating revenue while continuing its research and development opportunities.

Veritas Pharma Inc. is a publicly traded company in Canada, on the Canadian Securities Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.

For more information, please visit our website:

On behalf of the Board of Directors

Peter McFadden
Interim Chief Executive Officer & CFO

Further information about the Company is available on our website at or under our profile on SEDAR at, and on the CSE website at

Investor and Public Relations Contact
Veritas Pharma Inc. Telephone: +1.416.918.6785
Email: [email protected] Website:

The Veritas Newsletter

Enter your email to receive news alerts and updates from Veritas Pharma.

You have Successfully Subscribed!